Advertisement

Reactions Weekly

, Volume 1709, Issue 1, pp 243–243 | Cite as

Tamoxifen

Ovarian small cell carcinoma of pulmonary type: case report
Case report
  • 17 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

A 46-year-old woman developed ovarian small cell carcinoma of pulmonary type during treatment with tamoxifen.

The woman, who had a history of left breast cancer, had undergone mastectomy and sentinel lymph node biopsy in 2013. The post-operative pathology showed an invasive ductal carcinoma of the left breast. She had been receiving treatment with oral tamoxifen 20mg daily for 2 years. In August 2015, she experienced abdominal distension, anorexia, dyschezia and weight loss of 6 months duration. A chest CT scan revealed multiple enlarged lymph nodes of mediastinal para-aortic arch. Abdominal and pelvic CT scanning identified a huge pelvic tumour and ascites. The tumour was approximately 15.8 × 10cm in size, and revealed a mixed pattern of multi-cystic and solid parts. Tumour...

Reference

  1. Yin L, et al. Primary ovarian small cell carcinoma of pulmonary type with coexisting endometrial carcinoma in a breast cancer patient receiving tamoxifen: A case report and literature review. [Review]. Medicine 97: e10900, No. 23, Jun 2018. Available from: URL: http://doi.org/10.1097/MD.0000000000010900 - China

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations